SLC35A2 and epilepsy: Patients affected with SLC35A2-CDG display hypogalactosylation of N-glycans and severe neurological symptoms such as epilepsy, intellectual disability, cerebral atrophy, and hypotonia [7,8,9,10,11,12,13,14].